SK Chemicals said it has released for sale in the domestic market a cell-culture influenza vaccine, SKYCellflu, which received a nod South Korea's Ministry of Food and Drug Safety in March to ramp up production after receiving marketing authorization in December last year.
For celebrity campaigns in the U.S., pharma often goes to Hollywood. In India, it's Bollywood--and Sanofi Pasteur is doing just that. The Sanofi vaccines venture tapped popular actor and director Farhan Akhtar to launch its latest flu immunization push in the country.
With its largest ever investment in a vaccine at stake, Sanofi is in the midst of rolling out the dengue fever vaccine it's worked on for 20 years at a cost of $1.5 billion. But through the launch, Sanofi hopes to recoup all of that expense--plus more.
Early signs of the upcoming flu season came this week as three vaccine makers--GlaxoSmithKline, Sanofi Pasteur and bioCSL--announced their first shipments of flu shots for the 2015-16 season, with two reporting that they will increase the amount of doses they deliver.
Two recently-published market analyses paint a picture of a competitive but growing vaccines field through 2020, with the newest report from Tufts University stating the industry is on track to post $40 billion in annual sales in 5 years.
Following behind a blockbuster is no easy task, but with a European Commission decision on Wednesday in favor of the vaccine, Merck's Gardasil 9 may just be up to the challenge of succeeding Gardasil.
Sanofi says it's poised to repeat the 7% growth its vaccines unit saw last year. But after battling through a slow quarter of influenza vaccine sales, it'll have some catching up to do during the remainder of the year if it wants to make that happen.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
Vietnam has become the 39th nation cleared for global exports of the vaccines it makes, joining an increasingly crowded field of local champions to multinational heavyweights. The World Health Organization gave that clearance recently for a country that expects to be a leading producer within the next 20 to 30 years.
Sanofi's highly anticipated dengue vaccine is being manufactured in a facility in France built specifically for the product. But expansion is also going on at Sanofi Pasteur's vaccine operation in Swiftwater, PA, in preparation for a launch of the vax which may happen later this year.